Published 18:27 IST, December 29th 2023
FDA imposes clinical hold on Iovance's lung cancer trial after patient death, shares plummet
Iovance shares dropped 26.9% premarket amid concerns about LN-145 TIL therapy's pre-conditioning regimen.
Representative | Image:
Unsplash
- Listen to this article
- 2 min read
Advertisement
20:39 IST, December 27th 2023